Traws Pharma, Inc. Increase (Decrease) in Accrued Liabilities
Traws Pharma, Inc. (TRAW) reported Increase (Decrease) in Accrued Liabilities of $753.00 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2016-11-14
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2016-09-30 was -$1.36M.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2016-06-30 was $1.95M.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2016-03-31 was $162.00K, a 76.00% decline year-over-year.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2015-09-30 was -$283.00K, a 138.35% decline year-over-year.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2014 was -$43.00K, a 102.27% decline from fiscal 2013.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2013 was $1.89M, a 26.39% decline from fiscal 2012.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2012 was $2.57M, a 129.12% increase from fiscal 2011.
- Traws Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2011 was $1.12M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2016-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $591.00K derived: sum of 2 quarters · filed 2016-11-14 | $753.00K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.11M 10-Q · filed 2016-08-15 | ||
| 2016-03-31 | $162.00K 10-Q · filed 2016-05-11 | |||
| 2015-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$1.44M derived: sum of 2 quarters · filed 2016-11-14 | -$765.00K 10-Q · filed 2016-11-14 | -$2.19M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$482.00K 10-Q · filed 2016-08-15 | -$1.91M derived: sum of 3 quarters · filed 2016-08-15 | -$1.17M derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | $675.00K 10-Q · filed 2016-05-11 | -$750.00K derived: sum of 2 quarters · filed 2016-05-11 | -$12.00K derived: sum of 3 quarters · filed 2016-05-11 | -$1.34M derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | -$687.00K derived: sum of 2 quarters · filed 2015-11-12 | -$2.02M derived: sum of 3 quarters · filed 2015-11-12 | -$43.00K 10-K · filed 2015-03-30 |
| 2014-09-30 | $738.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$593.00K derived: sum of 2 quarters · filed 2015-11-12 | $1.38M 10-Q · filed 2015-11-12 | -$616.00K derived: sum of 4 quarters · filed 2015-11-12 |
| 2014-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $644.00K 10-Q · filed 2015-08-13 | -$1.35M derived: sum of 3 quarters · filed 2015-08-13 | $1.13M derived: sum of 4 quarters · filed 2015-08-13 |
| 2014-03-31 | $1.98M 10-Q · filed 2015-05-15 | -$23.00K derived: sum of 2 quarters · filed 2015-05-15 | $2.46M derived: sum of 3 quarters · filed 2015-05-15 | $2.23M derived: sum of 4 quarters · filed 2015-05-15 |
| 2013-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $481.00K derived: sum of 2 quarters · filed 2015-03-30 | $260.00K derived: sum of 3 quarters · filed 2015-03-30 | $1.89M 10-K · filed 2015-03-30 |
| 2013-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $2.26M derived: sum of 2 quarters · filed 2014-11-14 | $3.89M 10-Q · filed 2014-11-14 | $2.87M derived: sum of 4 quarters · filed 2015-03-30 |
| 2013-06-30 | -$221.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.41M 10-Q · filed 2014-08-14 | $387.00K derived: sum of 3 quarters · filed 2015-03-30 | $1.34M derived: sum of 4 quarters · filed 2015-03-30 |
| 2013-03-31 | $1.63M 10-Q · filed 2014-05-15 | $608.00K derived: sum of 2 quarters · filed 2015-03-30 | $1.56M derived: sum of 3 quarters · filed 2015-03-30 | |
| 2012-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | -$71.00K derived: sum of 2 quarters · filed 2015-03-30 | $2.57M 10-K · filed 2015-03-30 | |
| 2012-09-30 | $955.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $3.60M 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | $2.64M 10-Q · filed 2013-09-06 | |||
| 2011-12-31 | $1.12M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |